BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 31809728)

  • 1. Atomoxetine Reestablishes Long Term Potentiation in a Mouse Model of Attention Deficit/Hyperactivity Disorder.
    Piña R; Rozas C; Contreras D; Hardy P; Ugarte G; Zeise ML; Rojas P; Morales B
    Neuroscience; 2020 Jul; 439():268-274. PubMed ID: 31809728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Shared and Unique Effects of Long-Term Administration of Methylphenidate and Atomoxetine on Degree Centrality in Medication-Naïve Children With Attention-Deficit/Hyperactive Disorder.
    Fu Z; Yuan J; Pei X; Zhang K; Xu C; Hu N; Xie R; Zhao Y; Wang Y; Yang L; Cao Q
    Int J Neuropsychopharmacol; 2022 Sep; 25(9):709-719. PubMed ID: 35524732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y; Yang L; Stein MA; Cao Q; Wang Y
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential long-term medication impact on executive function and delay aversion in ADHD.
    Rubio Morell B; Hernández Expósito S
    Appl Neuropsychol Child; 2019; 8(2):140-157. PubMed ID: 29244542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Atomoxetine and Osmotic Release Oral System-Methylphenidate on Executive Functions in Patients with Combined Type Attention-Deficit/Hyperactivity Disorder.
    Ince Tasdelen B; Karakaya E; Oztop DB
    J Child Adolesc Psychopharmacol; 2015 Aug; 25(6):494-500. PubMed ID: 26218871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
    Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
    Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential impact of methylphenidate and atomoxetine on sustained attention in youth with attention-deficit/hyperactivity disorder.
    Bédard AC; Stein MA; Halperin JM; Krone B; Rajwan E; Newcorn JH
    J Child Psychol Psychiatry; 2015 Jan; 56(1):40-8. PubMed ID: 24942409
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methylphenidate and atomoxetine treatment negatively affect physical growth indexes of school-age children and adolescents with attention-deficit/hyperactivity disorder.
    Deng L; Zhou P; Zhu L; Zhang Y; Yang T; Zhao Q; Chen J; Li T; Cheng Q; Chen L
    Pharmacol Biochem Behav; 2021 Sep; 208():173225. PubMed ID: 34217783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atomoxetine treatment in adults with attention-deficit/hyperactivity disorder.
    Walker DJ; Mason O; Clemow DB; Day KA
    Postgrad Med; 2015; 127(7):686-701. PubMed ID: 26343377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atomoxetine in the treatment of attention deficit hyperactivity disorder and suicidal ideation.
    Capuano A; Scavone C; Rafaniello C; Arcieri R; Rossi F; Panei P
    Expert Opin Drug Saf; 2014 Sep; 13 Suppl 1():S69-78. PubMed ID: 25171160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials.
    Liu Q; Zhang H; Fang Q; Qin L
    J Clin Exp Neuropsychol; 2017 Nov; 39(9):854-865. PubMed ID: 28052720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
    Roskell NS; Setyawan J; Zimovetz EA; Hodgkins P
    Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of atomoxetine and methylphenidate for problematic online gaming in adolescents with attention deficit hyperactivity disorder.
    Park JH; Lee YS; Sohn JH; Han DH
    Hum Psychopharmacol; 2016 Nov; 31(6):427-432. PubMed ID: 27859666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A 1.5-Year Follow-Up of Parent Training and Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms and Noncompliant/Disruptive Behavior in Autism.
    Arnold LE; Ober N; Aman MG; Handen B; Smith T; Pan X; Hyman SL; Hollway J; Lecavalier L; Page K; Rice R
    J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):322-330. PubMed ID: 29694241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylphenidate Restores Behavioral and Neuroplasticity Impairments in the Prenatal Nicotine Exposure Mouse Model of ADHD: Evidence for Involvement of AMPA Receptor Subunit Composition and Synaptic Spine Morphology in the Hippocampus.
    Contreras D; Piña R; Carvallo C; Godoy F; Ugarte G; Zeise M; Rozas C; Morales B
    Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dopamine transporter genotype influences the physiological response to medication in ADHD.
    Gilbert DL; Wang Z; Sallee FR; Ridel KR; Merhar S; Zhang J; Lipps TD; White C; Badreldin N; Wassermann EM
    Brain; 2006 Aug; 129(Pt 8):2038-46. PubMed ID: 16760197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder.
    Ni HC; Shang CY; Gau SS; Lin YJ; Huang HC; Yang LK
    Int J Neuropsychopharmacol; 2013 Oct; 16(9):1959-73. PubMed ID: 23672818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
    Nagy P; Häge A; Coghill DR; Caballero B; Adeyi B; Anderson CS; Sikirica V; Cardo E
    Eur Child Adolesc Psychiatry; 2016 Feb; 25(2):141-9. PubMed ID: 25999292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sub-chronic exposure to atomoxetine up-regulates BDNF expression and signalling in the brain of adolescent spontaneously hypertensive rats: comparison with methylphenidate.
    Fumagalli F; Cattaneo A; Caffino L; Ibba M; Racagni G; Carboni E; Gennarelli M; Riva MA
    Pharmacol Res; 2010 Dec; 62(6):523-9. PubMed ID: 20691787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Methylphenidate and Atomoxetine in Medication-Naive Children with Attention-Deficit Hyperactivity Disorder in a Real-World Setting.
    Zhang Y; Yin L; You C; Liu C; Dong P; Xu X; Zhang K
    Drugs R D; 2024 Mar; 24(1):29-39. PubMed ID: 37982991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.